VMS BioMarketing Celebrates OneVoice Program Triumph
VMS BioMarketing recently achieved significant recognition by winning the prestigious PM360 Trailblazer Award for its OneVoice program in the Patient/Consumer Education category. This honor reflects the company's commitment to enhancing patient services within the biopharma sector.
About the PM360 Trailblazer Awards
The PM360 Trailblazer Awards recognize outstanding initiatives in the biopharma industry. This annual competition highlights innovative programs that drive improvements in healthcare and patient experience. VMS BioMarketing's OneVoice program was not only a finalist in three categories but ultimately secured gold in Patient/Consumer Education, establishing its impact and effectiveness.
The Role of OneVoice
OneVoice is more than a program; it’s a comprehensive support system tailored to meet the individual needs of patients throughout their treatment journey. It integrates educational resources, logistical assistance, and emotional support into a single point of contact, ensuring continuous guidance from trained VMS Nurse Navigators.
Improving Patient Experiences
Abigail Mallon, the Chief Patient Experience & People Officer at VMS, emphasized the program's mission: "OneVoice provides patients with a cohesive, personalized journey with an advocate by their side." This approach is particularly crucial as the population of specialty pharmaceutical patients faces barriers that hinder effective treatment adherence, with reports suggesting that a substantial percentage of patients never fill their prescriptions or abandon treatment early.
Commitment to Patient Adherence
In today’s complex pharmaceutical landscape, ensuring that patients consistently follow their treatment plans is more vital than ever. VMS OneVoice aims to tackle the alarming statistics; approximately 20-30% of patients forgo starting their prescribed medications, while up to 50% discontinue their use within the year. By fostering real connections and leveraging the benefits of technology, OneVoice strives to enhance the patient experience significantly, thereby improving adherence rates and health outcomes.
Recognition and Future Directions
PM360, recognized as a leading trade magazine, plays a crucial role in highlighting key players in the biopharma marketing arena. The Trailblazer Awards are a testament to innovations that contribute to improved patient care. VMS BioMarketing, with its deep-rooted dedication to patient engagement, is well-positioned to continue making strides in this area.
About VMS BioMarketing
VMS BioMarketing stands at the forefront of patient engagement solutions, integrating human interaction, advanced technology, and real-world data to provide personalized support. With over 25 years in the industry, their One Voice model is designed to empower biopharma teams, ensuring each patient receives the appropriate mix of interventions tailored to their unique circumstances.
Frequently Asked Questions
What is VMS BioMarketing's OneVoice program?
The OneVoice program is a patient engagement initiative that offers personalized logistical, educational, and emotional support to patients during their treatment journey.
Why did VMS BioMarketing win the PM360 Trailblazer Award?
VMS BioMarketing won the award for excellence in Patient/Consumer Education through its innovative OneVoice program, which enhances patient support and adherence.
How does the OneVoice program improve patient adherence?
By providing real connections and support through trained Nurse Navigators, the program helps patients navigate their treatment journey effectively, improving adherence rates.
Who oversees the PM360 Trailblazer Awards?
The awards are judged by the PM360 Editorial Advisory Board, which consists of industry experts who evaluate the innovative efforts made within the biopharma industry.
What sets VMS BioMarketing apart in the industry?
VMS BioMarketing combines human connection with advanced technology and real-world data to deliver tailored patient support, leveraging over 25 years of experience in the field.
